o(6)-benzylguanine has been researched along with Glioma in 21 studies
O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To estimate the sustained (≥8 weeks) objective response rate in pediatric patients with recurrent or progressive high-grade gliomas (HGG, Stratum A) or brainstem gliomas (BSG, Stratum B) treated with the combination of O6-benzylguanine (O6BG) and temozolomide(®) (TMZ)." | 9.16 | A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. ( Balis, FM; Berg, SL; Boyett, JM; Geyer, JR; Goldman, S; Gururangan, S; Kun, LE; McLendon, RE; Minturn, JE; Packer, RJ; Pollack, IF; Poussaint, TY; Wallace, D; Warren, KE, 2012) |
| "This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide." | 9.14 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)." | 9.14 | Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas." | 9.10 | Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. ( Bigner, DD; Colvin, OM; Delaney, S; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Haglund, MM; Herndon, JE; Kaplan, R; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Tourt-Uhlig, S, 2002) |
| "Temozolomide (TMZ, 3,4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-as-tetrazine-8-carboxamide) is a new alkylating agent with promising antitumour efficacy for malignant gliomas." | 7.72 | Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. ( Germano, IM; Ito, H; Kanzawa, T; Kondo, S; Kondo, Y; Kyo, S, 2003) |
| "Temozolomide (TMZ) is a newly approved alkylating agent for the treatment of malignant gliomas." | 7.71 | Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. ( Berman, E; Gallo, JM; Ma, J; Murphy, M; O'Dwyer, PJ; Reed, K, 2002) |
| "Temozolomide (TMZ) is a DNA alkylating agent currently used as adjuvant treatment for anaplastic astrocytomas." | 5.32 | Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. ( Bedwell, J; Germano, IM; Kanzawa, T; Kondo, S; Kondo, Y, 2003) |
| "To estimate the sustained (≥8 weeks) objective response rate in pediatric patients with recurrent or progressive high-grade gliomas (HGG, Stratum A) or brainstem gliomas (BSG, Stratum B) treated with the combination of O6-benzylguanine (O6BG) and temozolomide(®) (TMZ)." | 5.16 | A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. ( Balis, FM; Berg, SL; Boyett, JM; Geyer, JR; Goldman, S; Gururangan, S; Kun, LE; McLendon, RE; Minturn, JE; Packer, RJ; Pollack, IF; Poussaint, TY; Wallace, D; Warren, KE, 2012) |
| "This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide." | 5.14 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)." | 5.14 | Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas." | 5.10 | Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. ( Bigner, DD; Colvin, OM; Delaney, S; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Haglund, MM; Herndon, JE; Kaplan, R; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Tourt-Uhlig, S, 2002) |
| "DNA alkylating agents including temozolomide (TMZ) and 1,3-bis[2-chloroethyl]-1-nitroso-urea (BCNU) are the most common form of chemotherapy in the treatment of gliomas." | 3.74 | The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. ( Chen, CC; D'Andrea, A; Taniguchi, T, 2007) |
| "Temozolomide (TMZ)-induced O6-methylguanine (MG) DNA lesions, if not removed by MG-DNA methyltransferase (MGMT), mispair with thymine, trigger rounds of futile mismatch repair (MMR), and in glioma cells lead to prolonged G2-M arrest and ultimately cell death." | 3.72 | Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. ( Berger, MS; Erickson, LC; Hirose, Y; Kreklau, EL; Pieper, RO, 2003) |
| "Temozolomide (TMZ, 3,4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-as-tetrazine-8-carboxamide) is a new alkylating agent with promising antitumour efficacy for malignant gliomas." | 3.72 | Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. ( Germano, IM; Ito, H; Kanzawa, T; Kondo, S; Kondo, Y; Kyo, S, 2003) |
| "Temozolomide (TMZ) is a newly approved alkylating agent for the treatment of malignant gliomas." | 3.71 | Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. ( Berman, E; Gallo, JM; Ma, J; Murphy, M; O'Dwyer, PJ; Reed, K, 2002) |
| "Temozolomide (TMZ) is a DNA alkylating agent currently used as adjuvant treatment for anaplastic astrocytomas." | 1.32 | Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. ( Bedwell, J; Germano, IM; Kanzawa, T; Kondo, S; Kondo, Y, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 14 (66.67) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, G | 1 |
| Zhao, L | 1 |
| Fan, T | 1 |
| Li, S | 1 |
| Zhong, R | 1 |
| Liu, C | 1 |
| Yao, S | 1 |
| Li, X | 1 |
| Wang, F | 1 |
| Jiang, Y | 1 |
| Quinn, JA | 5 |
| Jiang, SX | 3 |
| Reardon, DA | 5 |
| Desjardins, A | 4 |
| Vredenburgh, JJ | 3 |
| Rich, JN | 3 |
| Gururangan, S | 6 |
| Friedman, AH | 4 |
| Bigner, DD | 4 |
| Sampson, JH | 5 |
| McLendon, RE | 6 |
| Herndon, JE | 5 |
| Walker, A | 2 |
| Friedman, HS | 5 |
| Warren, KE | 1 |
| Geyer, JR | 1 |
| Poussaint, TY | 1 |
| Wallace, D | 1 |
| Balis, FM | 1 |
| Berg, SL | 1 |
| Packer, RJ | 1 |
| Goldman, S | 1 |
| Minturn, JE | 1 |
| Pollack, IF | 1 |
| Boyett, JM | 1 |
| Kun, LE | 1 |
| Hirose, Y | 1 |
| Kreklau, EL | 3 |
| Erickson, LC | 3 |
| Berger, MS | 1 |
| Pieper, RO | 1 |
| Kanzawa, T | 2 |
| Germano, IM | 2 |
| Kondo, Y | 2 |
| Ito, H | 1 |
| Kyo, S | 1 |
| Kondo, S | 2 |
| Bedwell, J | 1 |
| Pollok, KE | 1 |
| Bailey, BJ | 1 |
| Liu, N | 1 |
| Hartwell, JR | 1 |
| Williams, DA | 2 |
| Weingart, J | 3 |
| Brem, H | 2 |
| Dolan, ME | 5 |
| Delaney, SM | 2 |
| Vredenburgh, J | 1 |
| Rich, J | 1 |
| Pegg, AE | 4 |
| Moschel, RC | 4 |
| Birch, R | 1 |
| Provenzale, JM | 2 |
| Dancey, JE | 1 |
| Maxwell, J | 1 |
| Tourt-Uhlig, S | 2 |
| Chen, CC | 1 |
| Taniguchi, T | 1 |
| D'Andrea, A | 1 |
| Grossman, SA | 1 |
| Carson, KA | 1 |
| Fisher, JD | 1 |
| Rosenblum, ML | 1 |
| Olivi, A | 1 |
| Judy, K | 1 |
| Tatter, SB | 1 |
| Mineura, K | 2 |
| Izumi, I | 1 |
| Watanabe, K | 1 |
| Kowada, M | 2 |
| Kohda, K | 2 |
| Ikenaga, M | 1 |
| Fukuchi, M | 1 |
| Terashima, I | 1 |
| Kurpad, C | 1 |
| Rhines, LD | 1 |
| Sampath, P | 1 |
| Tyler, BM | 1 |
| Kokkinakis, DM | 1 |
| Bocangel, DB | 1 |
| Schold, SC | 1 |
| Ma, J | 1 |
| Murphy, M | 1 |
| O'Dwyer, PJ | 1 |
| Berman, E | 1 |
| Reed, K | 1 |
| Gallo, JM | 1 |
| Pluda, J | 1 |
| Delaney, S | 1 |
| Kaplan, R | 1 |
| Colvin, OM | 1 |
| Haglund, MM | 1 |
| Stine, L | 1 |
| Mitchell, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Newly Diagnosed (Part 1) or Recurrent/Progressive (Parts 1 and 2) Cerebral Anaplastic Gliomas[NCT00006474] | Phase 1 | 0 participants | Interventional | 2001-03-31 | Completed | ||
| Phase I GLIADEL and Continuous Infusion of Intravenous O6-Benzylguanine Trial in Patients With Recurrent Malignant Glioma[NCT00004892] | Phase 1 | 0 participants | Interventional | 2000-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for o(6)-benzylguanine and Glioma
| Article | Year |
|---|---|
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resi | 2009 |
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2009 |
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Dacarbazine; DNA M | 2012 |
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease P | 2005 |
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carm | 2002 |
14 other studies available for o(6)-benzylguanine and Glioma
| Article | Year |
|---|---|
Investigations on the effect of O(6)-benzylguanine on the formation of dG-dC interstrand cross-links induced by chloroethylnitrosoureas in human glioma cells using stable isotope dilution high-performance liquid chromatography electrospray ionization tand
Topics: Alkylating Agents; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Deoxycytid | 2014 |
iRGD-mediated core-shell nanoparticles loading carmustine and O
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cell Line, Tum | 2017 |
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Survival; Colony | 2003 |
Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Division; Dacarbazine; DNA-Binding Proteins; Dos | 2003 |
Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repa | 2003 |
Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Carmustine; Glioma; Guanin | 2003 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
Potential of O6-methylguanine or O6-benzylguanine in the enhancement of chloroethylnitrosourea cytotoxicity on brain tumours.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Basal Ganglia; Brain Neoplasms; Cell Count; | 1994 |
[Study on potentiation of nitrosourea-cytotoxicity by DNA repair enzyme inhibitors in human brain tumor cells].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Drug Resis | 1997 |
Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Enzyme Inhibitors; Female; | 1999 |
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2000 |
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2001 |
Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; | 2002 |
Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.
Topics: Animals; Brain Neoplasms; Cricetinae; Dose-Response Relationship, Drug; Female; Glioma; Guanine; Hum | 1990 |